Macrilen

Active Ingredient(s): Macimorelin Acetate
FDA Approved: * December 20, 2017
Pharm Company: * AETERNA ZENTARIS
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Macrilen Overview

Macimorelin (INN) is a drug being developed by Æterna Zentaris for use in the diagnosis of adult growth hormone deficiency. As of January 2014, it is in Phase III clinical trials.[1] The phase III trial for growth hormone deficiency is expected to be complete in December 2016.[2] Macimorelin is a growth hormone secretagogue receptor (ghrelin receptor) agonist causing release of growth hormone from the pituitary gland.[3][4][5] See also List of growth hormone secretagogues Reference...

Read more Macrilen Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Macimorelin

Recent Macrilen Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Macrilen: (1 result)

Sorted by National Drug Code

• 71090-002 Macrilen 60 mg/mg Oral Granule, for Solution by Strongbridge U.S. Inc

Other drugs which contain Macimorelin Acetate or a similar ingredient: (1 result)